When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Aversa Fentanyl holds the potential to become the world’s first abuse-deterrent opioid patch.

Alvogen has issued a nationwide recall of one lot of Fentanyl Transdermal System 25 patches because the patches may stick ...

When it comes to the safe use of synthetic opioids like fentanyl, precise dosing of the powerful pain meds is key. Now, ...

A mid-stage study reveals that transdermal estradiol patches may match traditional androgen deprivation therapy in treating prostate cancer with fewer side effects. This approach boosts bone density ...

Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange ...

Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall is that there is a potential that patches ...

The expected issuance of this patent further expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its ...

Alvogen Inc. is recalling 1 lot of Fentanyl Transdermal System 25mcg/h transdermal patches due to the potential for multi-stacked patches (adhered one on top of the other) in a single product pouch.

ORLANDO - Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, has announced an exclusive partnership with Kindeva Drug Delivery to develop Aversa™ Fentanyl, a potential ...

Report with market evolution powered by AI - The global nicotine patch market size is estimated to grow by USD 494.1 million ...